Dr Shadman on the Comparative Efficacy of Currently Available BTK Inhibitors in CLL
Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.
Stay updated with breaking news from Innovators Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.
Mazyar Shadman, MD, MPH, details the efficacy of BTK inhibitors in the frontline treatment of CLL as well as safety considerations in the relapsed/refractory setting.
Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib ...
The jury reviewed each pre-selected application based on five endorsement criteria: extraordinary contribution to the field, sustainable practice, international recognition, continuous learning, and international collaboration.
Michigan has received a “special dishonorable mention” from a prominent watchdog group for its plans to spend more than $1.5 billion in federal taxpayer mon